Galecto Inc
GLTO3.420USD
+0.215+6.71%
Handelsschluss 08/04, 16:00（ET）Kurse um 15 Minuten verzögert
4.52MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Galecto Inc Unternehmen
Galecto, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel treatments for cancer and liver diseases. The Company’s pipeline consists small molecule drug candidates that target cancer and fibrosis signaling pathways, including an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and a preclinical dual inhibitor of ENL-YEATS and FLT3 (BRM-1420) for multiple genetic subsets of acute myeloid leukemia (AML). The GB1211, is also being developed for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
Unternehmensinformationen
BörsenkürzelGLTO
Name des UnternehmensGalecto Inc
IPO-datumOct 29, 2020
CEODr. Hans T. Schambye, M.D., Ph.D.
Anzahl der mitarbeiter5
WertpapierartOrdinary Share
GeschäftsjahresendeOct 29
Addresse75 State Street
StadtBOSTON
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl02109
Telefon14570705210
Websitehttps://galecto.com/
BörsenkürzelGLTO
IPO-datumOct 29, 2020
CEODr. Hans T. Schambye, M.D., Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Garrett Winslow
Mr. Garrett Winslow
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
1.43K
+41.63%
Lori Firmani
Lori Firmani
Interim Chief Financial Officer
Interim Chief Financial Officer
692.00
+48.82%
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Director
Independent Director
192.00
--
Mr. Matthew (Matt) Kronmiller
Mr. Matthew (Matt) Kronmiller
Executive Vice President of Strategy, Chief Business Officer
Executive Vice President of Strategy, Chief Business Officer
--
--
Dr. Anne Prener, M.D., Ph.D.
Dr. Anne Prener, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Jayson D.A. Dallas, M.D.
Dr. Jayson D.A. Dallas, M.D.
Independent Director
Independent Director
--
--
Dr. Carl M. Goldfischer, M.D.
Dr. Carl M. Goldfischer, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Hans T. Schambye, M.D., Ph.D.
Dr. Hans T. Schambye, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Amy Wechsler
Dr. Amy Wechsler
Independent Director
Independent Director
--
--
Dr. David M. Shapiro, M.D.
Dr. David M. Shapiro, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Garrett Winslow
Mr. Garrett Winslow
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
1.43K
+41.63%
Lori Firmani
Lori Firmani
Interim Chief Financial Officer
Interim Chief Financial Officer
692.00
+48.82%
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Director
Independent Director
192.00
--
Mr. Matthew (Matt) Kronmiller
Mr. Matthew (Matt) Kronmiller
Executive Vice President of Strategy, Chief Business Officer
Executive Vice President of Strategy, Chief Business Officer
--
--
Dr. Anne Prener, M.D., Ph.D.
Dr. Anne Prener, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Jayson D.A. Dallas, M.D.
Dr. Jayson D.A. Dallas, M.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Wed, Jul 9
Aktualisiert: Wed, Jul 9
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Novo Holdings A/S
7.56%
Goldfischer (Carl S)
3.17%
Danmarks Eksport- og Investeringsfond
2.23%
Renaissance Technologies LLC
1.16%
Squarepoint Capital LLP
0.98%
Other
84.90%
Aktionäre
Aktionäre
Anteil
Novo Holdings A/S
7.56%
Goldfischer (Carl S)
3.17%
Danmarks Eksport- og Investeringsfond
2.23%
Renaissance Technologies LLC
1.16%
Squarepoint Capital LLP
0.98%
Other
84.90%
Aktionärstypen
Aktionäre
Anteil
Venture Capital
9.79%
Individual Investor
3.69%
Investment Advisor/Hedge Fund
1.81%
Investment Advisor
1.54%
Hedge Fund
1.28%
Research Firm
0.10%
Other
81.80%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
59
239.46K
18.11%
-271.19K
2025Q1
62
239.03K
18.78%
-252.12K
2024Q4
60
217.43K
16.55%
-284.28K
2024Q3
59
203.99K
16.06%
-298.69K
2024Q2
60
348.76K
31.45%
-134.50K
2024Q1
63
345.52K
32.40%
-164.48K
2023Q4
60
341.29K
32.01%
-179.28K
2023Q3
64
397.38K
37.18%
-170.79K
2023Q2
66
515.37K
50.18%
-71.94K
2023Q1
67
465.15K
45.46%
-174.31K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Novo Holdings A/S
99.91K
7.56%
--
--
Mar 31, 2025
Goldfischer (Carl S)
41.96K
3.17%
+1.00
+0.00%
Apr 15, 2025
Danmarks Eksport- og Investeringsfond
29.52K
2.23%
-29.52K
-50.00%
Sep 30, 2024
Renaissance Technologies LLC
15.34K
1.16%
+300.00
+1.99%
Mar 31, 2025
Squarepoint Capital LLP
12.98K
0.98%
+283.00
+2.23%
Mar 31, 2025
Susquehanna International Group, LLP
10.72K
0.81%
+10.72K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
10.89K
0.82%
+1.93K
+21.48%
May 31, 2025
The Vanguard Group, Inc.
8.85K
0.67%
--
--
May 31, 2025
Schambye (Hans T.)
3.40K
0.26%
+1.00
+0.03%
Apr 15, 2025
Tower Research Capital LLC
1.58K
0.12%
+1.58K
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Aug 28, 2024
Merger
25<1
Aug 28, 2024
Merger
25<1
Aug 28, 2024
Merger
25<1
Aug 28, 2024
Merger
25<1
Datum
Art
Verhältnis
Aug 28, 2024
Merger
25<1
Aug 28, 2024
Merger
25<1
Aug 28, 2024
Merger
25<1
Aug 28, 2024
Merger
25<1
